Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial

Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial

Abstract Background A previous Phase I/II study demonstrated that TAS‐102 (trifluridine/tipiracil [FTD/TPI]) plus bevacizumab (Bev) has encouraging efficacy and controllable safety for patients with previously treated metastatic colorectal cancer. Therefore, we designed for assessing the efficacy an...

Full description

Bibliographic Details
Main Authors: Eiji Oki, Akitaka Makiyama, Yuji Miyamoto, Masahito Kotaka, Hirofumi Kawanaka, Keisuke Miwa, Akira Kabashima, Tomohiro Noguchi, Kotaro Yuge, Tomomi Kashiwada, Koji Ando, Mototsugu Shimokawa, Hiroshi Saeki, Yoshito Akagi, Hideo Baba, Yoshihiko Maehara, Masaki Mori
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Cancer Medicine
Subjects:
bevacizumab
colorectal cancer
elderly
thymidine phosphorylase inhibitor
Trifluridine
Online Access:https://doi.org/10.1002/cam4.3618

Internet

https://doi.org/10.1002/cam4.3618

Similar Items